314768-96-2

Basic information

• Product Name: 2-AMINO-5-PYRROLIDINOBENZAMIDE
• Synonyms: 2-AMINO-5-PYRROLIDINOBENZAMIDE
• CAS NO: 314768-96-2
• Molecular Formula: C₁₁H₁₅N₃O
• Molecular Weight: 205.26
• Mol File: 314768-96-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMINO-5-PYRROLIDINOBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-PYRROLIDINOBENZAMIDE(314768-96-2)
• EPA Substance Registry System: 2-AMINO-5-PYRROLIDINOBENZAMIDE(314768-96-2)

Safety Data

• Hazardous Substances Data: 314768-96-2(Hazardous Substances Data)

Upstream product

• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 41994-44-9 5-chloro-2-nitrobenzoyl chloride 
• 40763-96-0 2-nitro-5-chlorobenzamide 
• 299897-90-8 2-nitro-5-(pyrrolidin-1-yl)benzamide 

Downstream Products

• 299897-92-0 2-(3'-Methoxyphenyl)-6-(pyrrolidinyl)-4-quinazolinone 

Relevant articles and documents

GLUCOSE UPTAKE INHIBITORS

this invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

Molecular modelling, synthesis, cytotoxicity and anti-tumour mechanisms of 2-aryl-6-substituted quinazolinones as dual-targeted anti-cancer agents

Background and Purpose Our previous study demonstrated that 6-(pyrrolidin-1-yl)-2-(3-methoxyphenyl)quinazolin-4-one (HMJ38) was a potent anti-tubulin agent. Here, HMJ38 was used as a lead compound to develop more potent anti-cancer agents and to examine t

CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS

Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.